Navigation Links
Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes
Date:4/29/2008

NEW YORK, April 29 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has agreed to sell $1.6 billion of senior unsecured notes: $600 million in aggregate principal amount of 5.450% notes due May 1, 2018 and $1 billion in aggregate principal amount of 6.125% notes due May 1, 2038 in an underwritten public offering.

Banc of America Securities LLC, J.P. Morgan Securities Inc., and Morgan Stanley are acting as representatives of the underwriters.

Bristol-Myers Squibb intends to use the net proceeds from the offering to finance the repayment of its $400 million principal amount of the 4.00% Notes due August 2008, to finance redemptions of its $1.2 billion principal amount of Floating Rate Convertible Debentures due 2023 at the option of holders in 2008 and general corporate purposes. The offering is expected to close on May 1, 2008.

The prospectus supplement and accompanying prospectus related to the offering of the notes may be obtained by contacting one of the following representatives:

Banc of America Securities, LLC

Capital Markets Operations

100 West 33rd Street, 3rd Floor

New York, NY 10001

Telephone: 800-294-1322

J.P. Morgan Securities Inc.

270 Park Avenue, 8th Floor

New York, NY 10017

Telephone: 212-834-4533

Morgan Stanley and Company, Inc.

180 Varick Street 2/F

New York, NY 10014

Attention: Prospectus Department

Telephone: 866-718-1649

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb's business, including those identified in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2007, particularly under "Item 1A. Risk Factors". Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical and related health care products company whose mission is to extend and enhance human life.


'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
5. Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
6. EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2007 on January 31
9. Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
10. Bristol-Myers Squibb Announces Dividend
11. Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... Premier executive recruitment firm, Slone Partners, is proud ... Hunt Scanlon Media. , Hunt Scanlon Media is one of the most ... news source in the human capital sector. , “It is a great honor for ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... The Conference ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel ... country specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel , March ... a leading developer of adult stem cell technologies for ... Chief Executive Officer, will provide an update on new ... nd Annual Neuroscience Biopartnering and Investment Forum, being ... York Academy of Sciences. ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... interfere with the ability of endogenous hormones to regulate homeostasis via their ... activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and immunological disorders. EDC ...
Breaking Biology Technology:
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:2/28/2017)... 28, 2017 News solutions for biometrics, bag ... ... from 14 to 16 March, Materna will present its complete ... seamless travel is a real benefit for passengers. To accelerate ... their passenger touch point solutions to take passengers through the complete ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
Breaking Biology News(10 mins):